The rapidly aging population desperately requires new therapies for Alzheimer's disease.
Despite years of pharmaceutical research, limited clinical success has been realized, with …

Innate immunity is associated with Alzheimer's disease, but the influence of immune
activation on the production of amyloid-β is unknown,. Here we identify interferon-induced …

γ-Secretases are a group of widely expressed, intramembrane-cleaving proteases involved
in many physiological processes. Their clinical relevance comes from their involvement in …

Alzheimer's disease is the most common form of dementia, characterized by two
pathological hallmarks: amyloid-β plaques and neurofibrillary tangles. The amyloid …

Development of γ-secretase inhibitors (GSIs) and modulators (GSMs) represents an
attractive therapeutic opportunity for Alzheimer's disease (AD) and cancers. However, how …

Near-infrared fluorescence (NIRF) molecular imaging has been widely applied to monitoring
therapy of cancer and other diseases in preclinical studies; however, this technology has not …

The development of Alzheimer's disease (AD) drugs has recently witnessed substantial
achievement. To further enhance the pool of drug candidates, it is crucial to explore non …

A potent γ-secretase modulator (GSM) has been developed to circumvent problems
associated with γ-secretase inhibitors (GSIs) and to potentially enable use in primary …

Importance Although considerable effort has been expended developing drug candidates
for Alzheimer disease, none have yet succeeded owing to the lack of efficacy or to safety …

Alzheimer's disease (AD) is the most common form of progressive neurodegenerative
disorder, marked by memory loss and a decline in cognitive function. The major hallmarks of …